Pulmonary vasodilators in patients with advanced chronic kidney disease and pre-capillary pulmonary hypertension-A case series.

Autor: Leguizamon R; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., McLaren I; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., John T; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., Khan R; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., Prendergast A; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., Wattanachayakul P; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., Geller A; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., Malin J; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., Jarret SA; Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA., Lo KB; Department of Cardiology, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts USA., Martinez Manzano JM; Department of Pulmonary and Critical Care Medicine Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA., Witzke C; Department of Cardiology Jefferson Einstein Hospital Philadelphia Pennsylvania USA.
Jazyk: angličtina
Zdroj: Respirology case reports [Respirol Case Rep] 2024 Sep 19; Vol. 12 (9), pp. e70027. Date of Electronic Publication: 2024 Sep 19 (Print Publication: 2024).
DOI: 10.1002/rcr2.70027
Abstrakt: Pulmonary hypertension (PH) is a prevalent complication among patients with chronic kidney disease (CKD). In these patients, pulmonary vasodilators may be useful but are underused. We describe a group of patients with precapillary PH and advanced CKD treated with pulmonary vasodilators. This was a case series of patients with CKD stage 4 and 5 and precapillary PH (isolated or combined) based on right heart catheterization (RHC) treated with pulmonary vasodilators from 2018 to 2023. Of 263 patients with isolated precapillary or combined PH and advanced CKD, only 17 (6%) were treated with pulmonary vasodilators; 53% ( n  = 9) with precapillary PH and 47% ( n  = 8) with combined PH. Most patients (94%, n  = 16) received phosphodiesterase-5 antagonists, while 12% ( n  = 2) received endothelin receptor antagonists. Adverse clinical outcomes were seen in 35% of patients within a year. The use of pulmonary vasodilator did not prevent adverse outcomes in patients with precapillary PH and advanced CKD.
Competing Interests: Given the adherence to ethical and institutional guidelines and the main incentive of academic growth without monetary incentive for the development of this study, the authors declare no conflicts of interest present in this study.
(© 2024 The Author(s). Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje